News

This application represents the first chimeric antigen receptor (CAR) T-cell therapy submitted to the EMA. Axicabtagene ciloleucel is currently under review by the U.S. Food and Drug Administration

GC4419 is a novel dismutase mimetic designed to prevent the damaging effects of radiation in normal tissue by rapidly converting superoxide to hydrogen peroxide, and is currently in

The transaction will help LabCorp create leading expertise in the oncology segment by combining the extensive experience of Covance in late phase with the deep expertise of Chiltern

Adapalene and benzoyl peroxide gel 0.1%/2.5% is a combination of adapalene, a retinoid, and benzoyl peroxide, and is indicated for the topical treatment of acne vulgaris in patients

Maviret is intended to be taken daily once for eight weeks. It is free from ribavirin and is a pan-genotypic treatment for patients not suffering from cirrhosis and

PFS is one of the three primary endpoints in the randomised, open-label, multi-centre, global trial, dubbed MYSTIC, which compared Imfinzi as a monotherapy or in combination with tremelimumab

The focus will be on a range of newly discovered RNA modulating enzyme targets. Evotec and STORM have been collaborating since 2016 in high-throughput screening and structural biology

In its letter to Eagle, the FDA has requested that the Company conduct an additional clinical trial for RYANODEX for Exertional Heat Stroke. “We are reviewing our options

The British pharma giant also said that it is weighing options for its Rare Diseases business which it is looking to divest in the near future following a